Pub Date : 2018-01-01DOI: 10.25179/TJEM.2018-61243
Guzin Cakmak, B. I. Aydoğan, C. Ersöz, E. Ozkan, S. Sak, S. Güllü
{"title":"Relation of 18F-FDG PET/CT Positivity with Tumor Cytopathology, Galectin-3, PTEN, Ki-67 and NIS Expressions in Thyroid Nodules","authors":"Guzin Cakmak, B. I. Aydoğan, C. Ersöz, E. Ozkan, S. Sak, S. Güllü","doi":"10.25179/TJEM.2018-61243","DOIUrl":"https://doi.org/10.25179/TJEM.2018-61243","url":null,"abstract":"","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"277 1","pages":"176-182"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75424654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/tjem.20182202-s32
G. Yalin, S. Doğanşen, A. Salmaslioglu, S. Tanrikulu, S. Yarman
{"title":"Evaluation of the Relationship Between Thyroid Nodules and Disease Activity in Patients with Acromegaly","authors":"G. Yalin, S. Doğanşen, A. Salmaslioglu, S. Tanrikulu, S. Yarman","doi":"10.25179/tjem.20182202-s32","DOIUrl":"https://doi.org/10.25179/tjem.20182202-s32","url":null,"abstract":"","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"37 12 1","pages":"8-9"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78333306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/TJEM.20182202-S09
H. Sav, U. Mousa
Introduction: Obesity is a public health problem involving both children and adults with an increasing prevalence in the World and North Cyprus. In this study we aimed to determine the prevalence of childhood obesity in our country and plan future studies. Subjects and Methods: In May-June 2007, we collected demographic, anthropometric and nutritional data of 7832 students between 12-15 years of age studying in 29 different secondary schools. We determined that the prevalence of obesity was 13.7% (1073); overweight 18.3% (1433); low body weight 3.5% (274). We invited 274 children in the obese group to our department of Endocrinology and Metabolism for anthropometric and metabolic analyses. Results: Two hundred and seventy four (53.6%) were girls and 127 (46.4%) were boys. The median age was 13.66. According to the National Cholesterol Education Program Adult Treatment Panel – III criteria (NCEP ATP III). 122 (44.5%) were diagnosed as Metabolic Syndrome (MetS). The body mass index percentiles correlated positively with the waist circumference, hip circumference and HOMA IR score (r= 0.53; p<0.001; r=0.54. p<0.001; r=0.15; p<0.05 respectively). HOMA IR correlated positively with systolic blood pressure. diastolic blood pressure. triglycerides. hip circumference. fasting blood glucose and waist circumference (r=0.19; p<0.001; r=0.17. p<0.001; r=0.28; p<0.001; r=0.23; p<0.001; r=0.25; p<0.001; r=0.30; p<0.001 respectively). According to Receiver operated characteristics (ROC) curves. a HOMA IR score of ≥2.15 predicted MetS with 90% sensitivity and 20% specificity. A HOMA IR score of ≥ 5.35 predicted MetS with 90% specificity and 29% sensitivity (AUC 0.619. %95 CI: 0.552-0.686. p<0.001). The mean TSH level of subjects with MetS was higher than those without Mets (3.84±3.09 vs. 2.94±1.91; p=0.004). The free T4 levels were similar in both groups. The prevalence of diabetes in the family was similar in subjects with and without MetS [73/122 (59.8%) vs. 105/152 (69.1%). p=0.127]. Conclusion: The prevalence of childhood obesity and associated comorbidities are similar in North Cyprus with other Mediterranean countries. S-09
{"title":"Prevalence of Childhood Obesity and Associated Morbidities in North Cyprus","authors":"H. Sav, U. Mousa","doi":"10.25179/TJEM.20182202-S09","DOIUrl":"https://doi.org/10.25179/TJEM.20182202-S09","url":null,"abstract":"Introduction: Obesity is a public health problem involving both children and adults with an increasing prevalence in the World and North Cyprus. In this study we aimed to determine the prevalence of childhood obesity in our country and plan future studies. Subjects and Methods: In May-June 2007, we collected demographic, anthropometric and nutritional data of 7832 students between 12-15 years of age studying in 29 different secondary schools. We determined that the prevalence of obesity was 13.7% (1073); overweight 18.3% (1433); low body weight 3.5% (274). We invited 274 children in the obese group to our department of Endocrinology and Metabolism for anthropometric and metabolic analyses. Results: Two hundred and seventy four (53.6%) were girls and 127 (46.4%) were boys. The median age was 13.66. According to the National Cholesterol Education Program Adult Treatment Panel – III criteria (NCEP ATP III). 122 (44.5%) were diagnosed as Metabolic Syndrome (MetS). The body mass index percentiles correlated positively with the waist circumference, hip circumference and HOMA IR score (r= 0.53; p<0.001; r=0.54. p<0.001; r=0.15; p<0.05 respectively). HOMA IR correlated positively with systolic blood pressure. diastolic blood pressure. triglycerides. hip circumference. fasting blood glucose and waist circumference (r=0.19; p<0.001; r=0.17. p<0.001; r=0.28; p<0.001; r=0.23; p<0.001; r=0.25; p<0.001; r=0.30; p<0.001 respectively). According to Receiver operated characteristics (ROC) curves. a HOMA IR score of ≥2.15 predicted MetS with 90% sensitivity and 20% specificity. A HOMA IR score of ≥ 5.35 predicted MetS with 90% specificity and 29% sensitivity (AUC 0.619. %95 CI: 0.552-0.686. p<0.001). The mean TSH level of subjects with MetS was higher than those without Mets (3.84±3.09 vs. 2.94±1.91; p=0.004). The free T4 levels were similar in both groups. The prevalence of diabetes in the family was similar in subjects with and without MetS [73/122 (59.8%) vs. 105/152 (69.1%). p=0.127]. Conclusion: The prevalence of childhood obesity and associated comorbidities are similar in North Cyprus with other Mediterranean countries. S-09","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"28 1","pages":"3-3"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82800628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/tjem.2018-60184
M. Mogarekar, Mahendra G. Dhabe, Mayuri Madhukarrao Palmate
D O I: 10 .2 51 79 /t je m .2 01 860 18 4 Objective: This study aims to investigate the role of paraoxonase 1 activity and Q192R polymorphism in the development of nephropathy in patients with Type 2 diabetes mellitus. Material and Methods: This case-control study included 100 patients with Type 2 diabetes mellitus for more than five years, admitted to our hospital. They were divided into two groups (with and without diabetic nephropathy) on the basis of albumin-creatinine ratio. Serum samples of all patients were subjected to paraoxonase 1 arylesterase activity, using phenylacetate as the substrate. Paraoxonase 1 phenotyping was carried out by calculating the ratio of inhibited arylesterase activity to non-inhibited arylesterase activity using phenylacetate and p-nitrophenyl acetate, respectively, as substrates. Results: Paraoxonase 1 arylesterase activity was found to be significantly lower in subjects with diabetic nephropathy than that in the subjects without diabetic nephropathy (85.4±24.12 vs. 127.94±25.51 p=0.01). Bothunivariate (Odds ratio=1.073, Neglekerke’s R2=0.565, area under the curve=0.888, p≤0.001) and multivariate (Odds ratio= 1.067, [95% confidence interval (1.023-1.113), p=0.003)] logistic tests showed independent, protective association of paraoxonase 1 arylesterase activity with the development of diabetic nephropathy. Paraoxonase 1 RR homozygous diabetic patients were observed to be significantly associated with diabetic nephropathy in the univariate logistic regression (R2=0.056 area under the curve=0.600 p=0.037), while the multivariate analysis did not show any significance. Conclusion: A decreased paraoxonase 1 arylesterase activity may be considered to be an additional risk factor in the development of nephropathy in diabetes mellitus. Paraoxonase 1 RR homozygous individuals may be at an increased risk of being affected by diabetic nephropathy.
{"title":"Paraoxonase 1 Activity and its Polymorphism in Type 2 Diabetic Nephropathy","authors":"M. Mogarekar, Mahendra G. Dhabe, Mayuri Madhukarrao Palmate","doi":"10.25179/tjem.2018-60184","DOIUrl":"https://doi.org/10.25179/tjem.2018-60184","url":null,"abstract":"D O I: 10 .2 51 79 /t je m .2 01 860 18 4 Objective: This study aims to investigate the role of paraoxonase 1 activity and Q192R polymorphism in the development of nephropathy in patients with Type 2 diabetes mellitus. Material and Methods: This case-control study included 100 patients with Type 2 diabetes mellitus for more than five years, admitted to our hospital. They were divided into two groups (with and without diabetic nephropathy) on the basis of albumin-creatinine ratio. Serum samples of all patients were subjected to paraoxonase 1 arylesterase activity, using phenylacetate as the substrate. Paraoxonase 1 phenotyping was carried out by calculating the ratio of inhibited arylesterase activity to non-inhibited arylesterase activity using phenylacetate and p-nitrophenyl acetate, respectively, as substrates. Results: Paraoxonase 1 arylesterase activity was found to be significantly lower in subjects with diabetic nephropathy than that in the subjects without diabetic nephropathy (85.4±24.12 vs. 127.94±25.51 p=0.01). Bothunivariate (Odds ratio=1.073, Neglekerke’s R2=0.565, area under the curve=0.888, p≤0.001) and multivariate (Odds ratio= 1.067, [95% confidence interval (1.023-1.113), p=0.003)] logistic tests showed independent, protective association of paraoxonase 1 arylesterase activity with the development of diabetic nephropathy. Paraoxonase 1 RR homozygous diabetic patients were observed to be significantly associated with diabetic nephropathy in the univariate logistic regression (R2=0.056 area under the curve=0.600 p=0.037), while the multivariate analysis did not show any significance. Conclusion: A decreased paraoxonase 1 arylesterase activity may be considered to be an additional risk factor in the development of nephropathy in diabetes mellitus. Paraoxonase 1 RR homozygous individuals may be at an increased risk of being affected by diabetic nephropathy.","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"46 1","pages":"151-157"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86699109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/TJEM.20182202-P113
G. Cansu, B. Taskiran
{"title":"Retrospective Analysis of Patients with Hypoparathyroidism","authors":"G. Cansu, B. Taskiran","doi":"10.25179/TJEM.20182202-P113","DOIUrl":"https://doi.org/10.25179/TJEM.20182202-P113","url":null,"abstract":"","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"48 1","pages":"47-47"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88535387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/TJEM.2018-59661
Masoume Akhbari, A. Biglari, M. Farahani, M. Khalili, F. Bandarian
{"title":"Expression Level of Circulating miR-93 in Serum of Patients with Diabetic Nephropathy","authors":"Masoume Akhbari, A. Biglari, M. Farahani, M. Khalili, F. Bandarian","doi":"10.25179/TJEM.2018-59661","DOIUrl":"https://doi.org/10.25179/TJEM.2018-59661","url":null,"abstract":"","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"29 1","pages":"78-84"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81218737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/TJEM.2018-59842
A. Bişgin
{"title":"LEPR Deficiency: Prevalence and Importance of a Novel Mutation and Significant Genetic Variants, Usually Underestimated","authors":"A. Bişgin","doi":"10.25179/TJEM.2018-59842","DOIUrl":"https://doi.org/10.25179/TJEM.2018-59842","url":null,"abstract":"","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"17 1","pages":"85-90"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87139729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/tjem.20182202-p129
E. Cagiltay, F. Akay
Objective: Clinical manifestations of GO are caused by the over compression of orbital tissues within the restricted orbital bone cavity. Impaired ocular blood flow may disrupt the retinal microstructure and functions.. In this study we aimed to investigate the macular and choroidal thickness changes in GO compared with healthy subjects. Materials and Methods: The study group comprised 50 adult patients with previously diagnosed Graves’ Disease with ophthalmopathy who were on anti-thyroid treatment. For the assessment of GO activity. VISA (vision. inflammation. strabismus. and appearance) inflammatory score was used. When euthryoidism was achieved without side effects. the patients were referred to the ophthalmology clinic for Spectraldomain optical coherence tomography (SD-OCT) evaluation. Results: Subfoveal. mean and temporal choroidal thicknesses were increased significantly in study group according to the controls. The mean choroidal thickness was elevated. Conclusions: This elevation is because of the retroorbital inflammation even in this non-severe GO group. Choroidal thickness might be affected from the venous obstruction and congestion in patients with GO. The elevation of the choroidal thickness might be an early sign of venous congestion that occurs before the elevation of intraocular pressure.
{"title":"Evaluation of Choroidal Thickness Changes in Euthyroid Graves’ Ophthalmopathy","authors":"E. Cagiltay, F. Akay","doi":"10.25179/tjem.20182202-p129","DOIUrl":"https://doi.org/10.25179/tjem.20182202-p129","url":null,"abstract":"Objective: Clinical manifestations of GO are caused by the over compression of orbital tissues within the restricted orbital bone cavity. Impaired ocular blood flow may disrupt the retinal microstructure and functions.. In this study we aimed to investigate the macular and choroidal thickness changes in GO compared with healthy subjects. Materials and Methods: The study group comprised 50 adult patients with previously diagnosed Graves’ Disease with ophthalmopathy who were on anti-thyroid treatment. For the assessment of GO activity. VISA (vision. inflammation. strabismus. and appearance) inflammatory score was used. When euthryoidism was achieved without side effects. the patients were referred to the ophthalmology clinic for Spectraldomain optical coherence tomography (SD-OCT) evaluation. Results: Subfoveal. mean and temporal choroidal thicknesses were increased significantly in study group according to the controls. The mean choroidal thickness was elevated. Conclusions: This elevation is because of the retroorbital inflammation even in this non-severe GO group. Choroidal thickness might be affected from the venous obstruction and congestion in patients with GO. The elevation of the choroidal thickness might be an early sign of venous congestion that occurs before the elevation of intraocular pressure.","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"17 1","pages":"53-54"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73081268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/tjem.20182202-p119
S. Aksan, M. Yalçın, A. Altinova, M. Akturk, F. Törüner
Objective: It has been reported that endothelial dysfunction may occur in Graves' disease. Endocan and vascular endothelial growth factor (VEGF) are thought to exhibit endothelial dysfunction. The increase in carotid intima media thickness (CIMT) is known to be the earliest change in endothelial dysfunction. In our study, it was aimed to investigate the levels of serum endocan and VEGF in Graves' disease, to perform PMSC measurements and to examine the relationship between these parameters. Method: 31 healthy volunteers with 31 known Graves' disease and age, gender, who had no other known disease, newly diagnosed and had no anti-thyroid therapy, were studied as a control group. Serve endocan and VEGF levels were measured in the Graves group after both treatment and euthyroidism, and these values were compared with the control group. Findings: Serum endocan levels were higher in the hyperthyroid Graves group than in the control group (0.68 (0.181.21) vs 0.49 (0.11-1.88) pg/ml, p=0.002). There was no significant difference between control group and control group (p>0.05). Serum VEGF levels were not significantly different between Graves and control group (p>0.05). The PFT measurement was higher in the hyperthyroid Graves group than in the control group (0.68±0.07 vs 0.47±0.06 mm, p<0.001). Graves group, which became euthyroid after antithyroid therapy, showed a decrease in CIMT compared to the control group (0.59±0.05 vs 0.47±0.06, p<0.001). There was a positive correlation between serum endocan levels and TSH (p<0.01), sT3, sT4, Anti-Tg and Anti-TPO (p<0.01, p<0.05, p<0.001). In multiple linear regression analysis, sT3 was found to be the most effective parameter on endocan (F=5.664, R2=0.106, p<0.05). Conclusion: Our findings suggest that serum levels of endocan are increased and related to sT3 in Graves' disease. Turk J Endocrinol Metab 2018;22(Suppl):S47
目的:有报道称格雷夫斯病可发生内皮功能障碍。内啡肽和血管内皮生长因子(VEGF)被认为表现出内皮功能障碍。颈动脉内膜中膜厚度(CIMT)的增加是内皮功能障碍的最早变化。在我们的研究中，目的是研究Graves病的血清内啡肽和VEGF水平，进行PMSC测量，并检查这些参数之间的关系。方法:健康志愿者31例，已知格雷夫斯病31例，年龄、性别，无其他已知疾病，新诊断，未接受抗甲状腺治疗，作为对照组。Graves组治疗后和甲状腺功能亢进后均测量血清内皮素和VEGF水平，并与对照组比较。结果:甲亢组血清内啡肽水平高于对照组(0.68 (0.181.21)vs 0.49 (0.11-1.88) pg/ml, p=0.002)。对照组与对照组之间无显著差异(p>0.05)。Graves组与对照组血清VEGF水平差异无统计学意义(p>0.05)。甲亢Graves组PFT测量值高于对照组(0.68±0.07 vs 0.47±0.06 mm, p<0.001)。Graves组经抗甲状腺治疗后甲状腺功能恢复正常，CIMT较对照组下降(0.59±0.05 vs 0.47±0.06,p<0.001)。血清内啡肽水平与TSH (p<0.01)、sT3、sT4、Anti-Tg、Anti-TPO呈正相关(p<0.01, p<0.05, p<0.001)。多元线性回归分析发现，sT3是对endocan最有效的参数(F=5.664, R2=0.106, p<0.05)。结论:我们的研究结果提示Graves病患者血清内啡肽水平升高并与sT3相关。中华内分泌杂志，2018;22(增刊):347
{"title":"Serum Endocan Levels in Graves' Disease","authors":"S. Aksan, M. Yalçın, A. Altinova, M. Akturk, F. Törüner","doi":"10.25179/tjem.20182202-p119","DOIUrl":"https://doi.org/10.25179/tjem.20182202-p119","url":null,"abstract":"Objective: It has been reported that endothelial dysfunction may occur in Graves' disease. Endocan and vascular endothelial growth factor (VEGF) are thought to exhibit endothelial dysfunction. The increase in carotid intima media thickness (CIMT) is known to be the earliest change in endothelial dysfunction. In our study, it was aimed to investigate the levels of serum endocan and VEGF in Graves' disease, to perform PMSC measurements and to examine the relationship between these parameters. Method: 31 healthy volunteers with 31 known Graves' disease and age, gender, who had no other known disease, newly diagnosed and had no anti-thyroid therapy, were studied as a control group. Serve endocan and VEGF levels were measured in the Graves group after both treatment and euthyroidism, and these values were compared with the control group. Findings: Serum endocan levels were higher in the hyperthyroid Graves group than in the control group (0.68 (0.181.21) vs 0.49 (0.11-1.88) pg/ml, p=0.002). There was no significant difference between control group and control group (p>0.05). Serum VEGF levels were not significantly different between Graves and control group (p>0.05). The PFT measurement was higher in the hyperthyroid Graves group than in the control group (0.68±0.07 vs 0.47±0.06 mm, p<0.001). Graves group, which became euthyroid after antithyroid therapy, showed a decrease in CIMT compared to the control group (0.59±0.05 vs 0.47±0.06, p<0.001). There was a positive correlation between serum endocan levels and TSH (p<0.01), sT3, sT4, Anti-Tg and Anti-TPO (p<0.01, p<0.05, p<0.001). In multiple linear regression analysis, sT3 was found to be the most effective parameter on endocan (F=5.664, R2=0.106, p<0.05). Conclusion: Our findings suggest that serum levels of endocan are increased and related to sT3 in Graves' disease. Turk J Endocrinol Metab 2018;22(Suppl):S47","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"33 1","pages":"49-49"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76235168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.25179/tjem.2018-59949
M. Cakir, A. Grossman
{"title":"The Diagnosis of Neuroendocrine Tumours: An Endocrine Perspective","authors":"M. Cakir, A. Grossman","doi":"10.25179/tjem.2018-59949","DOIUrl":"https://doi.org/10.25179/tjem.2018-59949","url":null,"abstract":"","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"76 1","pages":"117-144"},"PeriodicalIF":0.2,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83838240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：